

group (32.6% vs 21.8%), but without statistical significance. Seropositivity of various autoantibodies was comparable between those with and without LTBI. Basal and stimulated IFN- γ levels was lower in IGRA and autoantibodies positive group ($p=0.014$) compared to IGRA positive antibody negative group.

Conclusions This study showed higher prevalence of LTBI in antibody positive FDRs of SLE. Basal and stimulated IFN- γ levels were lower in antibody positive group, in contrast to SLE patients who have higher basal IFN- γ . Further longitudinal studies would be required to see the effect of these autoantibodies on LTBI and risk of progression to TB.

LP-170 PREDICTORS OF NEUROPSYCHIATRIC FLARES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM FIVE PHASE III CLINICAL TRIALS OF BELIMUMAB

¹Leonardo Palazzo, ¹Julius Lindblom*, ¹Nursen Cetrez, ¹Henri Ala, ^{1,2}Ioannis Parodis.
¹Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Sweden;
²Department of Rheumatology, Faculty of Medicine and Health, Örebro University, Sweden

10.1136/lupus-2023-KCR.246

Background Belimumab has shown ability to reduce flare rates in systemic lupus erythematosus (SLE), but little is known about its potential benefits in neuropsychiatric (NP)SLE. We investigated predictors of NP flares in SLE patients under standard therapy with or without add-on belimumab.

Methods Data from five clinical trials of belimumab in SLE (BLISS-52, BLISS-76, BLISS-NEA, BLISS-SC, EMBRACE) were utilised (N=3638). Flares were defined using the British Isles Lupus Assessment Group (BILAG) activity index. Predictors of flares were investigated throughout a 52-week follow-up using univariable and multivariable Cox regression. A subgroup analysis in patients with baseline NP BILAG E was performed to determine predictors of de novo NP flare. Organ damage was assessed using the SLICC/ACR Damage Index (SDI).

Results In total, 105 (2.9%) NP flares were documented. In multivariable analysis, male sex (HR: 2.37; 95% CI: 1.31–4.28; $p=0.004$), baseline NP BILAG B-D (HR: 5.91; 95% CI: 3.86–9.06; $p<0.001$), and high baseline SDI score (HR: 1.35; 95% CI: 1.21–1.50; $p<0.001$) were highly associated with NP flare development. Belimumab use yielded no clear protection. In a separate analysis of SDI domains, the NP domain (HR: 3.25; 95% CI: 2.72–3.88; $p<0.001$) was the strongest predictor of NP flare, with cognitive impairment (HR: 14.29; 95% CI: 9.22–22.14; $p<0.001$), transverse myelitis (HR: 21.89; 95% CI: 5.40–88.72; $p<0.001$), and neuropathy (HR: 8.87; 95% CI: 5.59–14.09; $p<0.001$) mainly driving this association. In the subgroup analysis of the NP BILAG E population, male sex was the strongest predictor of de novo NP flare (HR: 3.26; 95% CI: 1.51–7.04; $p=0.003$).

Conclusions Current or former NPSLE activity and established organ damage in the NP domain at baseline were the strongest predictors of NP flare. Whether belimumab treatment protects against NP events remains unclear.

LP-171 FIBROMYALGIA AND GLUCOCORTICOIDS USE DRIVES SELF-PERCEIVED DEPRESSION IN SYSTEMIC LUPUS ERYTHEMATOSUS: INSIGHTS FROM A LARGE PROSPECTIVE AND MULTICENTER STUDY USING RELESSERPROS REGISTER'S DATABASE.

¹Iñigo Rúa-Figueroa, ²Julia Martínez-Barrio, ³Norman Jiménez, ⁴María Galindo-Izquierdo, ⁵Esther Uriarte-Isacelaya, ⁶Antonio Fernandez-Nebro, ⁷Jaime Calvo, ⁶Sara Manrique-Ariza, ⁸Jose Rosas, ⁹Rocio Caño-Alameda, ¹⁰J. Naváez, ¹¹Inmaculada Ros, ¹²Elena Aurrecochea, ¹³Vicenç Torrente-Segarra, ¹⁴Clara Sanguesa, ¹⁵Mercedes Freire-González, ¹⁶Eva Tomero-Muriel, ¹⁷Loreto Horcada, ¹⁸Clara Moriano, ¹⁹Mireia Moreno, ²⁰Carlotia Laura-Iñiguez, ²¹Ricardo Blanco, ²²Ana Pérez-Gómez, ²³José Luis Andréu-Sánchez, ²⁴Sandra Garrote-Corral, ²⁵Santiago Muñoz-Fernández, ²⁶Gema Bonilla, ²⁷Nuria Lozano-Rivas, ²⁸Carlos A Montilla-Morales, ²⁹O Ibaranguoitia, ³⁰Lorena Expósito, ³¹Elia Vals-Pascual, ³²Angela Pecondon-Español, ³³Sergio Machín, ³⁴Eva Salgado-Perez, ¹Maria Celia-Erausquin, ³⁵Tarek Carlos Salman-Monte, ³⁶Raúl Menor-Almagro, ³⁷Alejandro Muñoz-Jimenez, ³⁸Irene Altobás-González, ³⁹Jorge Juan Frago-Gil, ³⁸Jose María Pego-Reigosa*.
¹Rheumatology, Hospital De Gran Canaria Doctor Negrin, Spain; ²Rheumatology, Hospital Gregorio Marañón, Spain; ³Rheumatology, Instituto De Investigación Sanitaria Galicia Sur, IRIDIS Group, Spain; ⁴Rheumatology, University Hospital October 12, Spain; ⁵Rheumatology, Donostia Unibertsitate Ospitalea, Spain; ⁶Rheumatology, Hospital Regional Universitario de Málaga, Spain; ⁷Rheumatology, Araba University Hospital, Spain; ⁸Rheumatology, Hospital Marina Baixa, Spain; ⁹Rheumatology, General University Hospital of Alicante, Spain; ¹⁰Rheumatology, Bellvitge University Hospital, Spain; ¹¹Rheumatology, Son Llàtzer Hospital, Spain; ¹²Rheumatology, Hospital Sierra Llana, Spain; ¹³Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Spain; ¹⁴Rheumatology, Germans Trias i Pujol Hospital, Spain; ¹⁵Rheumatology, University Hospital of A Coruña, Spain; ¹⁶Rheumatology, Hospital de La Princesa, Spain; ¹⁷Rheumatology, Navarra Hospital Complex, Spain; ¹⁸Rheumatology, University Hospital of León, Spain; ¹⁹Rheumatology, Hospital Parc Taulí de Sabadell, Spain; ²⁰Rheumatology, Hospital Lugo, Spain; ²¹Rheumatology, Marqués de Valdecilla University Hospital, Spain; ²²Rheumatology, Hospital Universitario Príncipe De Asturias, Spain; ²³Rheumatology, Puerta de Hierro Majadahonda University Hospital, Spain; ²⁴Rheumatology, Ramón y Caja Hospital, Spain; ²⁵Rheumatology, Infanta Sofia University Hospital, Spain; ²⁶Rheumatology, La Paz University Hospital, Spain; ²⁷Rheumatology, Hospital Clínico Universitario Virgen de la Arrixaca, Spain; ²⁸Rheumatology, Salamanca University Hospital, Spain; ²⁹Rheumatology, Basurto University Hospital, Spain; ³⁰Rheumatology, Hospital Universitario De Canarias, Spain; ³¹Rheumatology, Doctor Peset University Hospital, Spain; ³²Rheumatology, Miguel Servet University Hospital, Spain; ³³Rheumatology, Hospital Materno Infantil De Gran Canaria, Spain; ³⁴Rheumatology, Complejo Hospitalario Universitario De Ourense, Spain; ³⁵Rheumatology, Hospital Del Mar, Spain; ³⁶Rheumatology, Hospital Universitario De Jerez, Spain; ³⁷Rheumatology, Virgen Del Rocío University Hospital, Spain; ³⁸Rheumatology, Complejo Hospitalario Universitario De Vigo, Spain; ³⁹Rheumatology, La Fe University and Polytechnic Hospital, Spain

10.1136/lupus-2023-KCR.247

Background Little is known about depression in SLE. To evaluate the prevalence of depression and associated factors in a large, multicenter SLE cohort (RELESSER-PROS).

Methods Prospective longitudinal study of SLE patients answering positively to the depression question of the Lupus Impact Tracker (LIT) questionnaire (question number 7, LITQ7 'I was depressed') over 5 consecutive annual visits (V1 to V5). Self-perceived depression was answered from 0 ('none of the time') to 4 ('most of time'). Covariates with potential impact in depression were considered. Friedman test and GEE models were used.

Results 1463 patients were included. Mean age 55 years, 90% female. Mean disease duration: 14 years. Fibromyalgia was present in 5.7%. Glucocorticoids use ranged from 49.4% to 57%, depending on the visit. SLEDAI ranged from 0 to 2 and SDI from 1 to 2. Prevalence of 'depression any time' was